<code id='971DFDC58E'></code><style id='971DFDC58E'></style>
    • <acronym id='971DFDC58E'></acronym>
      <center id='971DFDC58E'><center id='971DFDC58E'><tfoot id='971DFDC58E'></tfoot></center><abbr id='971DFDC58E'><dir id='971DFDC58E'><tfoot id='971DFDC58E'></tfoot><noframes id='971DFDC58E'>

    • <optgroup id='971DFDC58E'><strike id='971DFDC58E'><sup id='971DFDC58E'></sup></strike><code id='971DFDC58E'></code></optgroup>
        1. <b id='971DFDC58E'><label id='971DFDC58E'><select id='971DFDC58E'><dt id='971DFDC58E'><span id='971DFDC58E'></span></dt></select></label></b><u id='971DFDC58E'></u>
          <i id='971DFDC58E'><strike id='971DFDC58E'><tt id='971DFDC58E'><pre id='971DFDC58E'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:fashion    Page View:374
          Adobe

          Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to expect smaller and fewer checks as well as possible market consolidation but not to abandon hope just yet as investments stabilize following a sharp drop-off.

          As customers — often health systems, payers, or employers — and backers plot how they’ll invest shrinking budgets, they’re increasingly savvy about metrics, investors told STAT. They’re also less interested in rapid growth, and more keen on startups that can demonstrate savings and efficiency.

          advertisement

          That’s a sharp contrast from the unrestrained health tech investments that peaked in 2021, fueled by a pandemic-era frenzy for virtual appointments, mental health care and app-based therapies.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology
          JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

          FogPharmaCEOMathaiMammenVenrockSANFRANCISCO—SixmonthsintohistenureasCEOofcancerstartupFogPharma,Math

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          New Medicare drug pricing powers could soon be upended in court

          DistrictcourtswillmakethefirstroundofdecisionssoononchallengestoMedicare'sdrugpricenegotiationprogra